Publication | Closed Access

Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis: Osimertinib vs. first-generation EGFR tyrosine kinase inhibitors

Neuro-oncologySurvival OutcomesMedicinePathologyBronchial NeoplasmBaseline Cns MetastasisCancer TreatmentOncologyRadiation OncologyLung Cancer